The debate over whether employers should cover costly GLP-1 medications often focuses on pharmacy spending. New research suggests the calculation may also need to include productivity.
A National Bureau of Economic Research study linked GLP-1 use to a 17% reduction in sick days. Although the study was observational rather than a randomized trial, its design offers reasonable confidence that treatment contributed to the improvement.
The findings suggest that effectively treating obesity and metabolic disease can produce benefits extending beyond weight loss. Better physical and mental health may translate into greater energy, improved productivity and fewer health-related absences.
“The larger takeaway is that effectively treating metabolic disease can create value well beyond the number on the scale,” said Laura Walmsley, chief commercial officer at metabolic-health company Virta Health.
Still, employers should not assume those gains automatically justify the medications’ high price. Evidence has not consistently shown that near-term healthcare savings offset GLP-1 costs. Employers should evaluate clinical outcomes, medication persistence, employee experience and whether results last—not simply the cost of each prescription.
For employers, the big challenge is balancing access, affordability and outcomes.
A sound strategy also requires support before, during and after treatment. Employees taking GLP-1s may need clinical oversight, help managing side effects, nutritional counseling and coaching. Plans should also provide effective alternatives for people who do not want the drugs, cannot tolerate them or do not respond meaningfully.
That support becomes particularly important when an employee wants to discontinue medication. Such decisions should be made by the patient and clinician, but nutrition therapy, biomarker monitoring and ongoing coaching may help reduce the risk of regaining weight.
In an observational Virta study, patients receiving continuous nutrition support maintained 85% of their weight loss one year after discontinuing GLP-1s. Walmsley contrasted that with an average of 33% maintained in standard clinical trials. The comparison does not establish that every patient can achieve similar results, but it points to the potential value of structured post-medication care.
“The goal should be to ensure that people have an effective path forward whether they continue a GLP-1, stop because it is not working or tolerable, or prefer a non-prescription approach from the outset,” Walmsley said.
For employers, the big challenge is balancing access, affordability and outcomes. That means establishing evidence-based eligibility standards, negotiating an effective pharmacy strategy and pairing medication with comprehensive care.
As Walmsley put it: “Ultimately, the strongest strategies help ensure each member receives the right treatment at the right time while maximizing the long-term clinical and financial value of the benefit.”